D. Zackova

发表

Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy

T. Pavlík, L. Dušek, H. Klamová, 2011, BMC medical research methodology.

The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia

U. Olsson‐Strömberg, J. Hasford, M. Baccarani, 2020, Leukemia.

Role of Treatment in the Appearance and Selection of BCR-ABL1 Kinase Domain Mutations

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

D. Colomer, I. Glauche, T. Lion, 2022, Leukemia.

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy

D. Colomer, I. Glauche, T. Lion, 2022, Leukemia.

Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects

P. Valent, H. Herrmann, I. Sadovnik, 2016, Oncotarget.

Considerations for Treatment‐free Remission in Patients With Chronic Myeloid Leukemia: A Joint Patient–Physician Perspective

G. Saglio, P. Westerweel, V. García-Gutiérrez, 2018, Clinical lymphoma, myeloma & leukemia.

Prospective analysis of low-level BCR–ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia

D. Dvořáková, J. Mayer, Z. Ráčil, 2014, Leukemia & lymphoma.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials

L. Dušek, H. Klamová, J. Mužík, 2013, Leukemia & lymphoma.

Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia

M. Haluzík, J. Mayer, Z. Ráčil, 2013, Haematologica.

Dasatinib treatment long-term results among imatinib-resistant/intolerant patients with chronic phase chronic myeloid leukemia are favorable in daily clinical practice

H. Klamová, Tereza Nečasová, J. Mayer, 2020, Leukemia & lymphoma.

Evaluation of two CE-IVD tests for BCR-ABL1 transcript monitoring of chronic myeloid leukemia patients

J. Mayer, A. Folta, D. Zackova, 2020, Leukemia & lymphoma.

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels

L. Dušek, H. Klamová, M. Karas, 2013, Cancer medicine.

Analysis of Mutations in the BCR-ABL1 Kinase Domain, Using Direct Sequencing

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular Diagnosis & Therapy.

Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.

D. Dvořáková, J. Mayer, Z. Ráčil, 2012, Molecular diagnosis & therapy.

Imatinib as the first‐line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: Can we compare real life data to the results from clinical trials?

L. Dušek, H. Klamová, J. Březinová, 2011, American journal of hematology.

Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.

H. Klamová, J. Moravcová, D. Dvořáková, 2010, Experimental hematology.

Hierarchical distribution of somatic variants in newly diagnosed chronic myeloid leukaemia at diagnosis and early follow‐up

J. Mayer, Z. Ráčil, Dagmar Smitalova, 2021, British journal of haematology.

Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia

H. Klamová, E. Faber, J. Mayer, 2010, American journal of hematology.

The Effect of Imatinib Treatment Duration on the Quality of the Life of Patients with Chronic Myeloid Leukemia

L. Dušek, J. Mayer, Z. Ráčil, 2013 .

Dasatinib in imatinib-resistant or -intolerant CML patients: data from the clinical practice of 6 hematological centers in the Czech Republic.

H. Klamová, J. Březinová, K. Michalová, 2010, Neoplasma.

Successful treatment of steroid-refractory hepatitic variant of liver graft-vs-host disease with pulse cyclophosphamide.

M. Navrátil, M. Doubek, J. Mayer, 2009, Experimental hematology.

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients – results from real-life prospective study

E. Faber, P. Žák, J. Mayer, 2020, Leukemia & lymphoma.

The BCR–ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy

Š. Pospíšilová, J. Šmardová, D. Dvořáková, 2013, Leukemia & lymphoma.

[Invasive aspergillosis in hematooncological patients: advantages and disadvantages of various diagnostic methods, treatment options and financial costs of therapy].

M. Navrátil, D. Dvořáková, J. Vorlíc̆ek, 2008, Vnitrni lekarstvi.

Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy

E. Koritáková, H. Klamová, E. Faber, 2018, American journal of hematology.

The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population†

D. Dvořáková, J. Mayer, Z. Ráčil, 2010, American journal of hematology.

Incidence of second malignancies during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors in the Czech Republic and Slovakia.

H. Klamová, K. Indrák, J. Mužík, 2011, Neoplasma.

Elucidation of protein interactions necessary for the maintenance of the BCR–ABL signaling complex

J. Mayer, L. Trantírek, P. Krejcí, 2019, Cellular and Molecular Life Sciences.

Current survival measures reliably reflect modern sequential treatment in CML: Correlation with prognostic stratifications

T. Pavlík, L. Dušek, H. Klamová, 2013, American journal of hematology.

Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-α administration

L. Dušek, R. Hájek, K. Indrák, 2003, Medical oncology.

Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR—final report from AFTER-SKI

U. Olsson‐Strömberg, S. Deneberg, J. Richter, 2021, Leukemia.

Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission

I. Glauche, H. Klamová, N. Cross, 2020, Leukemia.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry

M. Höglund, M. Baccarani, K. Indrák, 2017, Leukemia.

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

H. Klamová, J. Mužík, J. Dyr, 2014, Hematological oncology.

Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin

U. Olsson‐Strömberg, J. Hasford, M. Baccarani, 2019, American journal of hematology.

Treatment Patterns in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Third Line of TKI Therapy and Beyond Based on Real-World Evidence

D. Wormser, P. Westerweel, T. Sahmoud, 2021, Blood.

Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia

M. Piskacek, Andrea Knight, M. Jurajda, 2022, Cancer Immunology, Immunotherapy.

COVID-19 in Patients with Chronic Myeloid Leukemia: Poor Outcomes for Patients with Comorbidities, Older Age, Advanced Phase Disease, and Those from Low-Income Countries: An Update of the Candid Study

Q. Jiang, M. Mauro, F. Nicolini, 2021, Blood.

Novel Illumina‐based next generation sequencing approach with one‐round amplification provides early and reliable detection of BCR‐ABL1 kinase domain mutations in chronic myeloid leukemia

J. Mayer, Z. Ráčil, Dagmar Smitalova, 2020, British journal of haematology.

The significance of enzyme and transporter polymorphisms for imatinib plasma levels and achieving an optimal response in chronic myeloid leukemia patients

P. Žák, J. Maláková, J. Mayer, 2018, Archives of medical science : AMS.

The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia

H. Klamová, J. Mayer, Z. Ráčil, 2011, International journal of hematology.

Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR–ABL transcript causing false-negative results by standard polymerase chain reaction

J. Mayer, F. Rázga, D. Zackova, 2010, Leukemia & lymphoma.

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

E. Koritáková, H. Klamová, J. Horáček, 2019, Blood.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types

H. Klamová, J. Mayer, Z. Ráčil, 2011, Leukemia & lymphoma.